FEBS Letters · 1985 · 26 citations · 15 references
MedicinePharmacologyBiochemical PharmacologyMolecular PharmacologyPharmacodynamicsAtropine TherapyCholinergic PharmacologyAdenylate Cyclase RegulationAdenylate Cyclase SignalingAdenylyl Cyclase RegulationMuscarinic AgonistsMuscarinic Receptor PharmacologyMuscarinic ReceptorsPirenzepine TherapyTreatment With Atropine
The muscarinic agonist oxotremorine produced a linear dose-dependent increase in membrane fluidity of intact and viable human lymphocytes in vitro. This effect proved to be receptor-mediated because preincubation with 10(-5)M atropine shifted the dose-response curve one order of magnitude rightward. Pirenzepine preincubation did not affect membrane fluidity variation. A cGMP increase was also found after oxotremorine treatment. The results are discussed in terms of possible modulation of guanyl cyclase and adenyl cyclase through membrane fluidity variations.
15